Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'randomized withdrawal'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies / A. Y. HARDAN in Autism, 23-8 (November 2019)
[article]
Titre : Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies Type de document : Texte imprimé et/ou numérique Auteurs : A. Y. HARDAN, Auteur ; R. L. HENDREN, Auteur ; Michael G. AMAN, Auteur ; A. ROBB, Auteur ; R. D. MELMED, Auteur ; K. A. ANDERSEN, Auteur ; R. LUCHINI, Auteur ; R. RAHMAN, Auteur ; S. ALI, Auteur ; X. D. JIA, Auteur ; M. MALLICK, Auteur ; J. E. LATEINER, Auteur ; Rohan H. C. PALMER, Auteur ; S. M. GRAHAM, Auteur Article en page(s) : p.2096-2111 Langues : Anglais (eng) Mots-clés : Asperger's disorder Social Responsiveness Scale autism spectrum disorders clinical trial medication memantine pervasive developmental disorder-not otherwise specified randomized withdrawal school-age children Index. décimale : PER Périodiques Résumé : Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind, placebo-controlled withdrawal trial. MEM-MD-69 was an open-label extension trial in which participants from MEM-MD-68, MEM-MD-91, and open-label trial MEM-MD-67 were treated 48 weeks with memantine extended release. In MEM-MD-91, 517 (59.6%) participants were confirmed Social Responsiveness Scale responders at week 12; mean Social Responsiveness Scale total raw scores improved two to three times a minimal clinically important difference of 10 points. In MEM-MD-68, there was no difference between memantine and placebo on the primary efficacy parameter, the proportion of patients with a loss of therapeutic response (defined as 10-point increase from baseline in Social Responsiveness Scale total raw score). MEM-MD-69 exploratory analyses revealed mean standard deviation improvement in Social Responsiveness Scale total raw score of 32.4 (26.4) from baseline of the first lead-in study. No new safety concerns were evident. While the a priori-defined efficacy results of the double-blind trial were not achieved, the considerable improvements in mean Social Responsiveness Scale scores from baseline in the open-label trials were presumed to be clinically important. En ligne : http://dx.doi.org/10.1177/1362361318824103 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=407
in Autism > 23-8 (November 2019) . - p.2096-2111[article] Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies [Texte imprimé et/ou numérique] / A. Y. HARDAN, Auteur ; R. L. HENDREN, Auteur ; Michael G. AMAN, Auteur ; A. ROBB, Auteur ; R. D. MELMED, Auteur ; K. A. ANDERSEN, Auteur ; R. LUCHINI, Auteur ; R. RAHMAN, Auteur ; S. ALI, Auteur ; X. D. JIA, Auteur ; M. MALLICK, Auteur ; J. E. LATEINER, Auteur ; Rohan H. C. PALMER, Auteur ; S. M. GRAHAM, Auteur . - p.2096-2111.
Langues : Anglais (eng)
in Autism > 23-8 (November 2019) . - p.2096-2111
Mots-clés : Asperger's disorder Social Responsiveness Scale autism spectrum disorders clinical trial medication memantine pervasive developmental disorder-not otherwise specified randomized withdrawal school-age children Index. décimale : PER Périodiques Résumé : Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind, placebo-controlled withdrawal trial. MEM-MD-69 was an open-label extension trial in which participants from MEM-MD-68, MEM-MD-91, and open-label trial MEM-MD-67 were treated 48 weeks with memantine extended release. In MEM-MD-91, 517 (59.6%) participants were confirmed Social Responsiveness Scale responders at week 12; mean Social Responsiveness Scale total raw scores improved two to three times a minimal clinically important difference of 10 points. In MEM-MD-68, there was no difference between memantine and placebo on the primary efficacy parameter, the proportion of patients with a loss of therapeutic response (defined as 10-point increase from baseline in Social Responsiveness Scale total raw score). MEM-MD-69 exploratory analyses revealed mean standard deviation improvement in Social Responsiveness Scale total raw score of 32.4 (26.4) from baseline of the first lead-in study. No new safety concerns were evident. While the a priori-defined efficacy results of the double-blind trial were not achieved, the considerable improvements in mean Social Responsiveness Scale scores from baseline in the open-label trials were presumed to be clinically important. En ligne : http://dx.doi.org/10.1177/1362361318824103 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=407